Conference Report

2008 Genitourinary Cancers Symposium: Conference Report

Source: CCO Independent Conference Coverage of the 2008 Genitourinary Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

2008 Genitourinary Cancers Symposium: Conference Report

Faculty:
David I. Quinn, MD, PhD Nicholas J. Vogelzang, MD

CME CREDIT INFORMATION

Release Date: 04/25/08

Expiration Date: 04/24/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe results from clinical trials of novel agents for the treatment of patients with prostate cancer
Discuss the use of tyrosine kinase inhibitors, alone and in combinations, for the treatment of prostate and bladder cancers
Cite cardiovascular complications associated with targeted agents

Topics covered include:

Introduction
Treatment of Prostate Cancer With Abiraterone, a Novel Androgen Synthesis Inhibitor
Endothelin-A Receptor Antagonists in Prostate Cancer
Novel Tyrosine Kinase Inhibitors in Prostate Cancer
Prostate Cancer Data Summary
Bevacizumab Plus Interferon in Renal Cell Cancer
Bevacizumab Plus Sunitinib in Renal Cell Cancer
Cardiovascular Complications With Targeted Agents
Gemcitabine and Radiotherapy in Bladder Cancer
Tyrosine Kinase Inhibitors in Bladder Cancer
Other Topics in Bladder Cancer
Testicular Cancer
Translational Studies
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.